Current pharmacotherapeutic recommendations for acute pancreatitis

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 8, 2006, Pages 1017-1025

  De Waele, Jan J ^a   Hoste, Eric ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute pancreatitis; Antisecretory drugs; Lexipafant; Protease inhibitors

Indexed keywords

ACTIVATED PROTEIN C; AMIKACIN; AMPHOTERICIN B; ANGIOPEPTIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; APROTININ; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CORTICOSTEROID; DROTRECOGIN; FLUCONAZOLE; GABEXATE MESILATE; HYDROCORTISONE; IMIPENEM; LEXIPAFANT; MEROPENEM; METRONIDAZOLE; OCTREOTIDE; PLACEBO; POLYMYXIN B; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 10; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TOBRAMYCIN;

ACUTE PANCREATITIS; ANTIBIOTIC PROPHYLAXIS; BLEEDING; CASE MANAGEMENT; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; INFECTIOUS COMPLICATION; MORBIDITY; MORTALITY; NONHUMAN; PANCREAS NECROSIS; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPTIC SHOCK;

ANTI-INFLAMMATORY AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; HUMANS; MYCOSES; PANCREATITIS; PANCREATITIS, ACUTE NECROTIZING; PATIENT SELECTION; PRACTICE GUIDELINES; PROTEASE INHIBITORS; RESEARCH DESIGN;

EID: 33745469875     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.8.1017     Document Type: Review

References (84)

1. BRADLEY EL III: A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch. Surg. (1993) 128:586-590.
2. BALTHAZAR EJ: Acute pancreatitis: assessment of severity with clinical and CT evaluation. Radiology (2002) 223:603-613.
3. PUOLAKKAINEN P, VALTONEN V, PAANANEN A, SCHRODER T: C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis. Gut (1987) 28:764-771.
4. WILSON C, HEADS A, SHENKIN A, IMRIE CW: C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br. J. Surg. (1989) 76:177-181
5. FROSSARD JL, HADENGUE A, PASTOR CM: New serum markers for the detection of severe acute pancreatitis in humans. Am. J. Respir. Crit. Care Med. (2001) 164:162-170.
6. PEZZILLI R, MORSELLI-LABATE AM, MINIERO R et al.: Simultaneous serum assays of lipase and interleukin-6 for early diagnosis and prognosis of acute pancreatitis. Clin. Chem. (1999) 45:1762-1767.
7. POORAN N, INDARAM A, SINGH P, BANK S: Cytokines (IL-6, IL-8, TNF): early and reliable predictors of severe acute pancreatitis. J. Clin. Gastroenterol. (2003) 37:263-266.
8. CHEN CC, WANG SS, LEE FY, CHANG FY, LEE SD: Pro-inflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am. J. Gastroenterol. (1999) 94:213-218.
9. BHATIA M: Apoptosis versus necrosis in acute pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. (2004) 286:G189-G196.
10. GUKOVSKY I, GUKOVSKAYA AS, BLINMAN TA, ZANINOVIC V, OPANDOL SJ: Early NF-kappaB activation is associated with hormone-induced pancreatitis. Am. J. Physiol. (1998) 275:G1402-G1414.
11. BHATIA M, WONG FL, CAO Y et al: Pathophysiology of acute pancreatitis. Pancreatology (2005) 5:132-144.
12. BHATIA M, BRADY M, SHOKUHI S et al.: Inflammatory mediators in acute pancreatitis. J. Pathol. (2000) 190:117-125.
13. WILMER A: ICU management of severe acute pancreatitis. Eur. J. Intern. Med. (2004) 15:274-280.
14. DUGERNIER T, REYNAERT M, LATERRE PF: Early multi-system organ failure associated with acute pancreatitis: a plea for a conservative therapeutic strategy. Acta Gastroenterol. Belg. (2003) 66:177-183.
15. BUCHLER MW, GLOOR B, MULLER CA et al.: Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann. Surg. (2000) 232:619-626.
16. DE WAELE J, HOSTE E, BLOT S, DECRUYENAERE J, COLARDYN F: Intra-abdominal hypertension in patients with severe acute pancreatitis. Crit. Care (2005) 9:R452-R457.
17. LEPPANIEMI A, KEMPPAINEN E: Recent advances in the surgical management of necrotizing pancreatitis. Curr. Opin. Crit. Care (2005) 11:349-352.
18. BADEN H, JORDAL K, LUND F, ZACHARIAE F: Prophylactic and curative action of Trasylol in pancreatitis. A double-blind trial. Scand J. Gastroenterol. (1969) 4:291-295.
19. TRAPNELL JE, RIGBY CC, TALBOT CH, DUNCAN EH: A controlled trial of Trasylol in the treatment ofacute pancreatitis. Br. J. Surg. (1974) 61:177-182.
20. BUCHLER M, MALFERTHEINER P, UHL W et al.: Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology (1993) 104:1165-1170.
21. SETA T, NOGUCHI Y, SHIMADA T, SHIKATA S, FUKUI T. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur. J. Gastroenterol. Hepatol. (2004) 16:1287-1293.
22. SINGH VP, CHARI ST. Protease inhibitors in acute pancreatitis: lessons from the bench and failed clinical trials. Gastroenterology (2005) 128:2172-2174.
23. KECK T, BALCOM J, ANTONIU B et al.: Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. Surgery (2001) 130:175-181.
24. GREENBERG R, HADDAD R, KASHTAN H, KAPLAN O: The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J. Lab. Clin. Med (2000) 135:112-121.
25. LADAS SD, RAPTIS SA: Conservative treatment of acute pancreatitis: the use of somatostatin. Hepatogastroenterology (1992) 39:466-469.
26. PLANAS M, PEREZ A, IGLESIA R et al.: Severe acute pancreatitis: treatment with somatostatin. Intensive Care Med. (1998) 24:37-39.
27. CHOI TK, MOK F, ZHAN WH et al.: Somatostatin in the treatment of acute pancreatitis: a prospective randomised controlled trial. Gut (1989) 30:223-227.
28. D'AMICO D, FAVIA G, BIASTATO R et al.: The use of somatostatin in acute pancreatitis-results of a multicenter trial. Hepatogastroenterology (1990) 37:92-98.
29. LUENGO L, VICENTE V, GRIS F et al.: Influence of somatostatin in the evolution of acute pancreatitis. A prospective randomized study. Int. J. Pancreatol. (1994) 15:139-144.
30. GJORUP I, ROIKJAER O, ANDERSEN B et aL: A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg. Gynecol. Obstet. (1992) 175:397-400.
31. KARAKOYUNLAR O, SIVREL E, TANIR N, DENECLI AG: High dose octreotide in the management of acute pancreatitis. Hepatogastroenterology (1999) 46:1968-1972.
32. PARAN H, MAYO A, PARAN D et al.: Octreotide treatment in patients with severe acute pancreatitis. Dig. Dis. Sci. (2000) 45:2247-2251.
33. BECHEY-NEWMAN N: Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity. Dig. Dis. Sci. (1993) 38:644-647.
34. FIEDLER F, JAUERNIG G, KEIM V, RICHTER A, BENDER HJ: Octreotide treatment in patients with necrotizing pancrearitis and pulmonary failure. Intensive Care Med. (1996) 22:909-915.
35. MCKAY C, BAXTER J, IMRIE C: A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int. J. Pancreatol. (1997) 21:13-19.
36. NIKOU GC, ARNAOUTIS TP, GIAMARELLOS-BOURBOULIS EJ, et al.: The significance of the dosage adjustment of octreotide in the treatment of acute pancreatitis of moderate severity. Hepatogastroenterology (2001) 48:1754-1757.
37. BINDER M, UHL W, FRIESS H, MALFERTHEINER P, BUCHLER MW: Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion (1994) 55(Suppl. 1):20-23.
38. DI FRANCESCO V, ANGELINI G, BOVO P et al.: Effect of octreotide on sphincter of Oddi motility in patients with acute recurrent pancreatitis: a manometric study. Dig. Dis. Sci. (1996) 41:2392-2396.
39. UHL W, BUCHLER MW, MALFERTHEINER P et al.: A randomised, double-blind, multi-centre trial of octreotide in moderate-to-severe acute pancreatitis. Gut (1999) 45:97-104.
40. O'HAIR DP, HOFMANN RG, SCHROEDER H, WILSON SD: Octreotide in the treatment of acute pancreatitis: a prospective, randomized trial. Gastroenterology (1993) 104(Suppl. 4/P2):A326.
41. LEVY P, HASTIER P, AROTCARENA R et al.: Efficacy of lanreotide 30 mg on prevention of pain relapse after oral refeeding in patients with necrotizing acute pancreatitis. A Phase II prospective multi-centre study. Pancreatology (2004) 4:229-232.
42. MCKAY CJ, CURRAN F, SHARPLES C, BAXTER JN, IMRIE CW: Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br. J. Surg. (1997) 84:1239-1243.
43. KINGSNORTH AN, GALLOWAY SW, FORMELA LJ: Randomized, double-blind Phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br. J. Surg. (1995) 82:1414-1420.
44. JOHNSON CD, KINGSNORTH AN, IMRIE CW et at: Double-blind, randomised, placebo-controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut (2001) 48:62-69
45. GLOOR B, UHL W, TCHOLAKOV O et al.: Hydrocortisone treatment of early SIRS in acute experimental pancreatitis. Dig. Dis. Sci. (2001) 46:2154-2161.
46. OSMAN MO, JACOBSEN NO, KRISTENSEN JU, LARSEN CC, JENSEN SL: Beneficial effects of hydrocortisone in a model of experimental acute pancreatitis. Dig. Surg. (1999) 16:214-221.
47. EKLUND A, LEPPANIEMI A, KEMPPAINEN E, PETTILA V: Vasodilatory shock in severe acute pancreatitis without sepsis: is there any place for hydrocortisone treatment? Acta AnaesthesioL Scand. (2005) 49:379-384.
48. DEVIERE J, LE MOINE O, VAN LAETHEM JL et al.: IL- 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology (2001) 120:498-505.
49. COOK JW, KARAKOZIS S, KIM D et al.: Interleukin-10 attenuates pro-inflammatory cytokine production and improves survival in lethal pancreatitis. Am. Surg. (2001) 67:237-241.
50. RONGIONE AJ, KUSSKE AM, KWAN K et al.: IL-10 reduces the severity of acute pancreatitis in rats. Gastroenterology (1997) 112:960-967.
51. BERNARD GR, VINCENT JL, LATERRE PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. (2001) 344:699-709.
52. MACHALA W, WACHOWICZ N, KOMOROWSKA A, GASZYNSKI W: The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies. Med. Sci. Monit. (2004) 10:CS31-CS36.
53. MAURICE A, SEGUIN P, AGUILLON D, CHANAVAZ C, MALLEDANT Y: [Activated protein C treatment: experience about 23 patients in the operative period]. Ann. Fr. Anesth. Reanim. (2005) 24:343-346.
54. DE WAELE J, VOGELAERS D, DECRUYENAERE J, DE VOS M, COLARDYN F: Infectious complications of acute pancreatitis. Acta Clin. Belg. (2004) 59:90-96.
55. ISENMANN R, RAU B, BEGER HG: Bacterial infection and extent of necrosis are determinants of organ failure in patients with acute necrotizing pancreatitis. Br. J. Surg. (1999) 86:1020-1024.
56. GLOOR B, MULLER CA, WORNI M et al.: Late mortality in patients with severe acute pancreatitis. Br. J. Surg. (2001) 88:975-979.
57. LE MEE J, PAYE F, SAUVANET A et al.: Incidence and reversibility of organ failure in the course of sterile or infected necrotizing pancreatitis. Arch. Surg. (2001) 136:1386-1390.
58. BEGER HG, BUCHLER M, BITTNER R et al.: Necrosectomy and postoperative local lavage in necrotizing pancreatitis. Br. J. Surg. (1988) 75:207-212.
59. DE WAELE JJ, VOGELAERS D, BLOT S, COLARDYN F: Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin. Infect. Dis. (2003) 37:208-213.
60. CICALESE L, SAHAI A, SILERI P et al.: Acute pancreatitis and bacterial translocation. Dig. Dis. Sci. (2001) 46:1127-1132.
61. DIEBEL LN, DULCHAVSKY SA, BROWN WJ: Splanchnic ischaemia and bacterial translocation in the abdominal compartment syndrome. J. Trauma (1997) 43:852-855.
62. DIEBEL LN, DULCHAVSKY SA, WILSON RF: Effect of increased intra-abdominal pressure on mesenteric arterial and intestinal mucosal blood flow. J. Trauma (1992) 33:45-48.
63. SAINIO V, KEMPPAINEN E, PUOLAKKAINEN P et al.: Early antibiotic treatment in acute necrotising pancreatitis. Lancet (1995) 346:663-667.
64. PEDERZOLI P, BASSI C, VESENTINI S, CAMPEDELLI A: A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg. Gynecol. Obstet. (1993) 176:480-483.
65. NORDBACK I, SAND J, SAARISTO R, PAAJANEN H: Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis-a single-center randomized study. J. Gastrointest. Surg. (2001) 5:113-118.
66. DE WAELE JJ, HOSTE E, BLOT SI et al.: Perioperative factors determine outcome after surgery for severe acute pancreatitis. Crit. Care (2004) 8:R504-R511.
67. DELCENSERIE R, YZET T, DUCROIX JP: Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas (1996) 13:198-201.
68. ISENMANN R, RUNZI M, KRON M, et al.: Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology (2004) 126:997-1004.
69. DELLINGER EP, TELLADO JM, SOTO N: Prophylactic antibiotic treatment in patients with severe acute necrotizing pancreatitis: a double blind placebo controlled trial. Presented at the 45th Annual International Conference on AntimicrobialAgents and Chemotherapy. Washington, USA (2005) Abstr.K - 1374.
70. TOOULI J, BROOKE-SMITH M, BASSI C, et al.: Guidelines for the management of acute pancreatitis. J Gastroenterol. Hepatol. (2002) 17(Suppl.):SI5-S39.
71. UHL W, WARSHAW A, IMRIE C, et al.: IAP Guidelines for the Surgical Management of Acute Pancreatitis. Pancreatology (2002) 2:565-573.
72. BARON TH, MORGAN DE: Acute necrotizing pancreatitis. N. Engl. J. Med. (1999) 340:1412-1417.
73. DERVENIS C, JOHNSON CD, BASSI C et al.: Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int. J. Pancreatol. (1999) 25:195-210.
74. SHARMA VK, HOWDEN CW. Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. Pancreas (2001) 22:28-31.
75. MARAVI-POMA E, GENER J, ALVAREZ-LERMA F et al.: Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: a prospective, randomized, multicenter study comparing two regimens with imipcnem-cilastatin. Intensive Care Med. (2003) 29:1974-1980.
76. DE WAELE JJ, VOGELAERS D, HOSTE E, BLOT S, COLARDYN F: Emergence of antibiotic resistance in infected pancreatic necrosis. Arch. Surg. (2004) 139:1371-1375.
77. GLOOR B, SCHMIDT O, UHL W, BUCHLER MW. Acute pancreatitis: threat of fungal infection. Pancreatology (2001) 1:213-216.
78. NATHENS AB, CURTIS JR, BEALE RJ et al.: Management of the critically ill patient with severe acute pancreatitis. Crit. Care Med (2004) 32:2524-2536
79. LUITEN EJ, HOP WC, LANGE JF, BRUINING HA: Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann. Surg. (1995) 222:57-65.
80. NATHENS AB, MARSHALL JC: Selective decontamination of the digestive tract in surgical patients: a systematic review of the evidence. Arch. Surg. (1999) 134:170-176.
81. GREWE M, TSIOTOS GG, LUQUE DE-LEON E, SARR MG: Fungal infection in acute necrotizing pancreatitis. J. Am. Coll. Surg. (1999) 188:408-414.
82. GOTZINGER P, SAUTNER T, KRIWANEK S et al.: Surgical treatment for severe acute pancrcatitis: extent and surgical control of necrosis determine outcome. World J. Surg. (2002) 26:474-478.
83. HOERAUF A, HAMMER S, MULLER-MYHSOK B, RUPPRECHT H: Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit. Care Med. (1998) 26:2010-2015.
84. MCKINNON PS, GOFF DA, KERN JW et al.: Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch. Surg. (2001) 136:1401-1408.